Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Immunotherapy and some other results from ESMO 2018

October 24, 2018 0

IMMUNOTHERAPY The Checkpoint Inhibitors The most revered news was the discovery of the checkpoint proteins on …

Positive News

October 22, 2018 0

The Week in Review #32 POSITIVE NEWS PROTEOSTASIS THERAPEUTICS Cystic Fibrosis Two days ago, a clinical-stage …

Why Portola’s stock decline

October 17, 2018 2

Why Portola’s Stock Decline Everybody interested in Portola (PTLA) knows by now that this firm has managed …

Why VTV Therapeutics’ stock added over 48% to its price before trading hours today

October 17, 2018 0

VTV Therapeutics’ (VTVT) stock price added over 48% before trading hours today. The news that some …

After being approved for Eczema, Regeneron’s and Sanofi’s product, Dupixent, succeeded in treating chronic rhinosinusitis, nasal polyps and asthma.

October 16, 2018 0

In two pivotal Phase 3 placebo-controlled trials Regeneron Pharmaceuticals’ (REGN) and Sanofi’s (SNY) drug, Dupixent® (dupilumab), demonstrated a …

Amgen’s product Amgevita, a biosimilar to adalimumab, will be launched in the European market today.

October 16, 2018 0

Amgen (AMGN) announced that AmgevitaTM, a biosimilar to adalimumab, will launch in markets across Europe beginning on October 16, …

Following the Stars. Less Science and More Logic

October 14, 2018 0

Prohost Letter #424 Following the Stars Less Science and More Logic We reiterate that while a …

$Exelixis initiates phase 3 trial with Cabometyx in radioiodine-refractory differentiated thyroid cancer (DTC) patients$

Exelixis initiates phase 3 trial with Cabometyx in radioiodine-refractory differentiated thyroid cancer (DTC) patients

October 9, 2018 0

Exelixis (EXEL) announced its initiation of a phase 3 pivotal trial (COSMIC-311) of Cabometyx (cabozantinib) in patients …

Spark Therapeutics: An encouraging attempt to dethrone enzyme replacement as the standard of care treatment for Pompe Disease.

October 9, 2018 0

On Saturday, October 6, 2018, Spark Therapeutics (ONCE) presented positive data from a preclinical trial with SPK-3006 …

Today’s Highlighted news is from …

October 5, 2018 0

Today, Prohost is highlighting news that could be transformative for a clinical-stage immunotherapy firm. The firm …

PTC Therapeutics: Solid data from its oral product Risdiplam in spinal muscular atrophy

October 4, 2018 0

PTC Therapeutics’ (PTCT) product Risdiplam demonstrated safety and tolerability at all the doses used in the …

The FDA granted Paratek two important product approvals. One is for acne

October 3, 2018 0

The U.S. Food and Drug Administration (FDA) has approved Paratek Pharmaceuticals’ (PRTK) product Seysara™ (sarecycline) for inflammatory lesions of non-nodular …

Outperformance, Underperformance and Volatility

October 2, 2018 0

The Week in Review #31 IN THE DEPARTED WEEK NOVEL MIGRAINE DRUGS ARE APPROVED ELI LILLY …

Seattle Genetics and Takeda Pharmaceutical Limited announced a successful trial on mature T-Cell lymphoma

October 1, 2018 0

Seattle Genetics (SGEN) and Takeda Pharmaceutical Limited (TKPYY) announced results from Phase 3 ECHELON-2 clinical trial evaluating Adcetris …

Antisense investigational product demonstrates successful results treating a life-threatening disease with no current treatment

September 27, 2018 0

The high risk of premature death from cardiovascular disease is believed to be caused by an …

AstraZeneca: Advancing and improving Stage III lung cancer treatments

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Immunotherapy and some other results from ESMO 2018

Positive News

Why Portola’s stock decline

Why VTV Therapeutics’ stock added over 48% to its price before trading hours today

After being approved for Eczema, Regeneron’s and Sanofi’s product, Dupixent, succeeded in treating chronic rhinosinusitis, nasal polyps and asthma.

Amgen’s product Amgevita, a biosimilar to adalimumab, will be launched in the European market today.

Following the Stars. Less Science and More Logic

Exelixis initiates phase 3 trial with Cabometyx in radioiodine-refractory differentiated thyroid cancer (DTC) patients

Spark Therapeutics: An encouraging attempt to dethrone enzyme replacement as the standard of care treatment for Pompe Disease.

Today’s Highlighted news is from …

PTC Therapeutics: Solid data from its oral product Risdiplam in spinal muscular atrophy

The FDA granted Paratek two important product approvals. One is for acne

Outperformance, Underperformance and Volatility

Seattle Genetics and Takeda Pharmaceutical Limited announced a successful trial on mature T-Cell lymphoma

Antisense investigational product demonstrates successful results treating a life-threatening disease with no current treatment

AstraZeneca: Advancing and improving Stage III lung cancer treatments

Three important news

The medical news of the year comes at the hands of Abott

A Bayer testing of Compugen’s checkpoint protein in human trial boosted our expectations for Compugen’s resurrection

About Portola’s appointment of a new president. Read Also: Why CRISPR lost $2.90 today